February 03, 2025
3 min watch
Save
VIDEO: ‘Encouraging’ data from two groups assessing blinatumomab, ponatinib in ALL
SAN DIEGO — In this video, Marlise R. Luskin, MD, MSCE, highlights updates from two groups evaluating blinatumomab and ponatinib for the treatment of acute lymphoblastic leukemia.
The phase 2 study analysis of blinatumomab (Blincyto, Amgen) and ponatinib (Iclusig, Takeda) from MD Anderson assessed prognosis, while a group from Italy looked at efficacy and toxicity.
“It’s really encouraging,” Luskin, a member of the adult leukemia program at Dana-Farber Cancer Institute and an associate professor of medicine at Harvard Medical School, told Healio.
References:
- Chiaretti S, et al. Abstract 835. Presented at: ASH Annual Meeting and Exhibition; Dec. 7-10, 2024; San Diego.
- Short NJ, et al. Abstract 837. Presented at: ASH Annual Meeting and Exhibition; Dec. 7-10, 2024; San Diego.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Luskin reports no relevant financial disclosures.